In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

This was the stock's second consecutive day of losses.

With patents locked up into the 2030s and rivals nowhere in sight, Vertex's CF fortress looks impregnable. The company has methodically built this position through years of innovation, leaving ...

Vertex Pharmaceuticals stock (NASDAQ ... For perspective, Vertex’s company-wide sales are around $11 billion currently. Journavx comes without the risk of addiction, likely making it a favorable ...

Vertex Pharmaceuticals (NASDAQ ... Is that just hype from a corporate executive? I don't think so. Journavx is the first new class of pain medication approved in over two decades.

Begin your TipRanks Premium journey today. Vertex Pharmaceuticals (VRTX) Company Description: Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex secured FDA approval for JOURNAVX, a non-opioid pain treatment, marking a significant advancement in pain management. The company reached a reimbursement agreement with NHS England for ...

Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 10 ...

The stock's fall snapped a four-day winning streak.